Shaily has signed eight contracts for pen and auto-injector platformsparticularly for semaglutide and related drugs with first commercial supplies in FY26, and is expanding pen manufacturing capacity from ~40 million to 8090 million pens a year, targeting both generic and innovator pharma in regulated and growth markets such as Canada and Brazil
Dry eye syndrome occurs when the eyes do not produce enough tears or when the tears evaporate too quickly
By combining these benefits, the Lipo-Mino Mix helps you tackle weight loss from multiple angles
Retatrutide (5mg-10mg), Triple Incretin Receptor Agonist Engineered Engagement of GLP-1, GIP, and Glucagon Receptors Introduction Engineered Engagement of GLP-1, GIP, and Glucagon Receptors Retatrutide is a synthetic 39-residue peptide engineered as a balanced agonist of three distinct class B G protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)
Cheng L, Jin H, Qiang Y, Wu S, Yan C, Han M, et al
